Daily Roundup

SKS.ASX TRJ.ASX BPT.ASX OFX.ASX EPN.ASX

Major Contract Award and FY26 Profit Upgrade

SKS Technologies Group Limited (ASX: SKS) has recently been awarded a range of contracts totalling $60 million across data centre and corporate clients, leading the company to revise its FY26 earnings guidance. Revenue is now expected to increase from the previous forecast of $320 million to $340 million, while the NPBT margin is expected to lift from 9% to 10%. These increases are expected to produce a profit before tax increase from $28.8 million to $34 million.

The revised outlook is based on a combination of new contract awards, a further record level of $325 million of work on hand, and a realistic confidence in future conversions from pipeline to contract award. The strong visibility of future earnings indicates the sustainable operating platform that the business has built as its work on hand has burgeoned, juggling growth and consolidation concurrently to harness the immediacy of opportunity in the data centre sector.

The recent contract awards totalling $60 million include a package for the NEXTDC M3 (Stage 4) data centre project and the full suite of SKS Technologies services for the new Melbourne office of Ernst and Young. These major contract awards demonstrate SKS Technologies' continued and unwavering pursuit of work across all of its traditional sectors.

Trajan Group maintains FY26 guidance

Trajan Group Holdings (ASX:TRJ) has provided a trading update ahead of its H1 FY26 financial results. The expected H1 FY26 results show a 'tale of two quarters', with Q1 being particularly soft, while Q2 indicates a return to growth. Group net revenue for H1 FY26 is expected to grow 3.8% to $84.1 million, compared to the previous corresponding period (PCP) of $81.0 million. However, Group normalised EBITDA (nEBITDA) is expected to be lower by $2.9 million in H1 FY26, at $5.0 million compared to $7.9 million in the PCP.

Despite the decline in nEBITDA for H1 FY26 compared to the PCP, Trajan maintains its FY26 guidance, with net revenue expected to exceed $170.0 million and group nEBITDA expected to exceed $16.0 million. The company expects margin expansion in H2 FY26 due to cost reductions from Project Neptune and pricing actions effective January 1, 2026.

Beach Energy FY26 half year results presentation

Beach Energy's FY26 half-year results demonstrate the company's commitment to operational excellence, safety, and environmental stewardship. The company achieved 12 months recordable injury-free across all operations, with no Process Safety Tier 1 or 2 events. The Waitsia Gas Plant ramp-up is underway, with the plant achieving a peak production rate of 165 TJ/day in January 2026. The company is targeting full nameplate capacity of 250 TJ/day through the commissioning of additional compressors in Q3 FY26.

Beach continues to invest in East Coast gas supply, with over $2 billion of capital invested over the past five years to discover and develop new gas resources. In H1 FY26, Beach delivered 18% of the total East Coast gas demand, supporting domestic energy security. The company's financial performance was solid, with $1 billion in total revenue and $558 million in underlying EBITDA.

Beach Energy FY26 half year results

Beach Energy Limited (ASX: BPT, Beach) today announced its FY26 first half results. Production of 9.5 MMboe was down 7% on H1 FY25, while sales revenue of $982 million was supported by four Waitsia LNG cargoes contributing $233 million. Underlying EBITDA was $558 million, and Underlying NPAT was $219 million.

Beach supplied more than 18% of East Coast gas demand in the first half, highlighting the critical role of domestic-only producers. The company maintains its FY26 production guidance of 19.7 - 22.0 MMboe and capital expenditure guidance of $675 - 775 million.

Strategic Review, 3Q26 Trading Update & CFO Resignation

OFX Group Ltd ('OFX') today announced the commencement of a strategic review to explore a range of organic and inorganic options seeking to maximize value for shareholders. The Board believes the long-term value of OFX is not reflected in the current share price, noting the company's robust global infrastructure, strong cash generation, and growth prospects through its 2.0 strategy.

OFX also provided a trading update for 3Q FY26, highlighting 44% growth in non-FX revenue, on-track migration of existing clients to the NCP, and continued progress in its product delivery program. However, Net Operating Income (NOI) was down 4% sequentially and 11.7% year-over-year, impacted by a softer macroeconomic environment and lower FX volatility. The company expects 2H FY26 NOI to be lower than the prior corresponding period.

Separately, OFX announced the resignation of its Chief Financial Officer, Ms. Selena Verth, after more than 8 years with the group. A search for a new CFO has commenced.

Epsilon Pharma signs manufacturing agreement with Puro NZ

Epsilon Healthcare's wholly owned subsidiary, Epsilon Pharma, has entered into a new manufacturing agreement with Puro New Zealand Limited ('Puro') to manufacture and prepare GMP certified finished formulation products for export to the UK and broader European region.

Based on Puro's volume forecasts, the Agreement represents manufacturing services revenue (to Epsilon) of approximately AU $2.0M (annualised) in FY2026 and approximately AU $6.0M over the initial 3-year term. This agreement is a milestone in Puro's evolution as a globally focused medicinal cannabis company, enabling the company to translate its organic, sun-grown New Zealand production into high-value finished products for patients and prescribers under the highest global standards.